# Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

> **NCT00599131** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 4 (actual)

## Conditions studied

- Cancer of Larynx

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Cetuximab
- **DRUG:** 5-Fluorouracil
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00599131
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08
- **Primary completion:** 2008-07
- **Final completion:** 2010-10
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The study was discontinued prematurely due to early stopping rules.
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00599131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00599131, "Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00599131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*